SUBSCRIBERS
Lonza in joint venture to develop biotherapeutic products
Published Wed, Apr 3, 2019 · 09:50 PM
'%3e%3cpath%20d='M20.7725%2026.9924C20.9555%2026.9924%2021.1297%2026.953%2021.2951%2026.8741C21.4604%2026.7953%2021.6346%2026.6694%2021.8177%2026.4965L27.8373%2020.8125C27.9848%2020.6752%2028.0865%2020.5353%2028.1425%2020.3929C28.1985%2020.2505%2028.2264%2020.1183%2028.2264%2019.9962C28.2264%2019.869%2028.1985%2019.7343%2028.1425%2019.5918C28.0865%2019.4494%2027.9848%2019.3095%2027.8373%2019.1722L21.8177%2013.5417C21.6142%2013.3484%2021.4375%2013.2098%2021.2875%2013.1259C21.1374%2013.042%2020.9708%2013%2020.7877%2013C20.5181%2013%2020.2981%2013.0916%2020.1278%2013.2747C19.9574%2013.4578%2019.8722%2013.6765%2019.8722%2013.9308V16.8147H19.6509C18.2827%2016.8147%2017.1014%2017.0258%2016.107%2017.448C15.1127%2017.8701%2014.2963%2018.4805%2013.658%2019.279C13.0197%2020.0776%2012.5466%2021.0402%2012.2389%2022.1668C11.9312%2023.2934%2011.7773%2024.5612%2011.7773%2025.9701C11.7773%2026.3006%2011.8575%2026.5537%2012.0177%2026.7291C12.1779%2026.9047%2012.3597%2026.9924%2012.5632%2026.9924C12.7259%2026.9924%2012.89%2026.9593%2013.0553%2026.8932C13.2206%2026.8271%2013.3693%2026.6719%2013.5016%2026.4278C13.9441%2025.5936%2014.4553%2024.9413%2015.0351%2024.4708C15.6149%2024.0004%2016.2838%2023.6685%2017.0417%2023.4752C17.7995%2023.2819%2018.6693%2023.1853%2019.6509%2023.1853H19.8722V26.0998C19.8722%2026.3591%2019.9574%2026.5728%2020.1278%2026.7406C20.2981%2026.9085%2020.513%2026.9924%2020.7725%2026.9924Z'%20fill='black'%20fill-opacity='0.85'/%3e%3c/g%3e%3crect%20x='0.5'%20y='0.5'%20width='39'%20height='39'%20rx='19.5'%20stroke='%23F2F2F2'/%3e%3cdefs%3e%3cclipPath%20id='clip0_715_28555'%3e%3crect%20width='16.4491'%20height='14'%20fill='white'%20transform='translate(11.7773%2013)'/%3e%3c/clipPath%3e%3c/defs%3e%3c/svg%3e){kind=small}
Singapore
SWISS biotech company Lonza has entered into an equal joint venture (JV) with Danish bioscience company Chr Hansen Holding to develop live biotherapeutic products (LBP) for pharma and biotech customers.
The phased investment of about 90 million euros (S$136.6 million) will be shared equally between the partners over three years.
'/%3e%3cpath%20d='M35.1847%2014.0422L9.37867%2024.1703C8.88772%2024.363%208.86989%2025.051%209.35015%2025.2688L15.0551%2027.8567C15.2097%2027.9269%2015.327%2028.0594%2015.3778%2028.2212L17.8255%2036.0078C17.9491%2036.4009%2018.4247%2036.5534%2018.7539%2036.3054L23.0143%2033.0968C23.2178%2032.9435%2023.4961%2032.9364%2023.7072%2033.0787L30.8526%2037.8975C31.2091%2038.1378%2031.6951%2037.9339%2031.7732%2037.5114L35.9896%2014.7059C36.0747%2014.2456%2035.6206%2013.8712%2035.1847%2014.0422Z'%20fill='%23FDFEFF'/%3e%3cpath%20d='M15.3125%2027.9998L30.4162%2018.627L19.3691%2029.3628L19.548%2033.3966L18.9531%2036.1248C18.3783%2036.7236%2017.9297%2036.2772%2017.8477%2036.0662L15.3681%2028.178L15.2734%2028.0233L15.3125%2027.9998Z'%20fill='%23C8DAEA'/%3e%3cpath%20d='M18.3594%2036.4259L19.3511%2029.3447L23.519%2032.9856C23.303%2032.9612%2023.1588%2032.9863%2023.0268%2033.0859L19.0712%2036.0718C18.6289%2036.4572%2018.4297%2036.4455%2018.3594%2036.4259Z'%20fill='%23A9C9DD'/%3e%3cdefs%3e%3clinearGradient%20id='paint0_linear'%20x1='33'%20y1='7.5'%20x2='19'%20y2='36.5'%20gradientUnits='userSpaceOnUse'%3e%3cstop%20stop-color='%231E96C8'/%3e%3cstop%20offset='1'%20stop-color='%2337AEE2'%20stop-opacity='0'/%3e%3c/linearGradient%3e%3c/defs%3e%3c/svg%3e)
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Luxury group Richemont reports slowdown in Q4 sales, appoints new CEO
Vietnam forfeits billions of US dollars in foreign aid amid anti-graft freeze
Asia: Stocks mixed after Wall Street, Europe retreat from records
Mapletree closes second Japan logistics development fund, expects 110 billion yen AUM
Dolce & Gabbana metaverse fashion offering leaves shopper fuming
Microsoft offers cloud customers AMD alternative to Nvidia AI processors
